Guggenheim Downgrades Nuvalent, Inc. to 'Hold'
Guggenheim analyst Brad Canino lowers Nuvalent, Inc. to 'Hold' with a $124 price target, a 0.61% upside from the current price.
Key Points
- Guggenheim analyst Brad Canino downgraded Nuvalent, Inc. to a 'Hold' rating with a price target of $124 on June 10, 2026.
- Guggenheim's $124 price target implies 0.61% upside from Nuvalent, Inc.'s ($NUVL) current $123.25 share price.
- Nuvalent's stock, trading at $123.25, has a market cap of $9.75 billion and a 52-week high of $123.62.
- Insiders including CEO James Porter recently sold shares, while several analysts set a consensus 'Hold' rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 10, 2026, Guggenheim analyst Brad Canino downgraded Nuvalent, Inc. (NasdaqGS: NUVL) from a previous rating to 'Hold', setting a price target of $124. This reflects a cautious stance on the biopharmaceutical company's stock, which was trading at $123.25.
Other Institutional Activity in Nuvalent, Inc.
Several other institutional investors have also adjusted their holdings in Nuvalent. Deerfield Management Company maintained its position with 17.25 million shares valued at approximately $1.77 billion. FMR LLC reduced its stake by 1.58 million shares, ending with 9.27 million shares worth about $950.22 million. Paradigm Biocapital Advisors LP increased its holdings by 55,000 shares, totaling 5.32 million shares valued at $545.49 million. BlackRock, Inc. added 19,524 shares, bringing its total to 4.82 million shares worth roughly $494.30 million.
Nuvalent, Inc. Stock Snapshot
Shares of Nuvalent, Inc. are trading near $123.25. The company, which operates in the biotechnology sector, has a market capitalization of $9.75 billion. Despite its clinical-stage status, Nuvalent is not currently profitable, reflected in a negative forward P/E ratio of -29.83. The stock has experienced a 52-week range from a low of $71.13 to a high of $123.62, with a beta of 1.153, indicating moderate volatility compared to the broader market.
$NUVL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Nuvalent, Inc.
Recent insider transactions at Nuvalent include sales by Chief Development Officer Darlene Noci, who sold 20,000 shares on June 9, 2026, under a planned transaction at an average price of $122.81. Additionally, President and CEO James Richard Porter sold 30,000 shares on June 8, 2026, also in a planned transaction at an average price of $88.53.
Analysts Set New Price Targets
On June 10, 2026, several analysts, including Guggenheim, TD Cowen, Barclays, and UBS, downgraded Nuvalent to 'Hold', each setting a price target of $124. The consensus among 16 analysts is a 'Hold', with an average target price of $128.13.
About Nuvalent, Inc.
Nuvalent, Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing therapies for cancer patients. Its key products include Zidesamtinib and Neladalkib, both designed to address resistance and adverse effects in cancer treatments. Led by CEO Dr. James R. Porter, the company employs 234 people and collaborates with Guardant Health, Inc. to develop companion diagnostics therapies.
Bottom Line
Guggenheim's downgrade of Nuvalent, Inc. to a 'Hold' rating reflects a cautious outlook amid recent insider sales and institutional adjustments. As a clinical-stage biopharma company, Nuvalent's stock remains of interest to investors tracking the biotechnology sector. It's important to note that analyst ratings are based on past performance and may not indicate future results.
Get Nuvalent, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NUVL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.